These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30564373)

  • 1. Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study.
    Johns I; Moschonas KE; Medina J; Ossei-Gerning N; Kassianos G; Halcox JP
    Open Heart; 2018; 5(2):e000849. PubMed ID: 30564373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease risk communication in NHS Health Checks using QRISK®2 and JBS3 risk calculators: the RICO qualitative and quantitative study.
    Gidlow CJ; Ellis NJ; Cowap L; Riley V; Crone D; Cottrell E; Grogan S; Chambers R; Clark-Carter D
    Health Technol Assess; 2021 Aug; 25(50):1-124. PubMed ID: 34427556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative examination of video-recorded NHS Health Checks: comparison of the use of QRISK2 versus JBS3 cardiovascular risk calculators.
    Gidlow CJ; Ellis NJ; Cowap L; Riley VA; Crone D; Cottrell E; Grogan S; Chambers R; Clark-Carter D
    BMJ Open; 2020 Sep; 10(9):e037790. PubMed ID: 32978197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors predicting statin prescribing for primary prevention: a historical cohort study.
    Finnikin S; Willis BH; Ryan R; Evans T; Marshall T
    Br J Gen Pract; 2021; 71(704):e219-e225. PubMed ID: 33558331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "They are saying it's high, but I think it's quite low": exploring cardiovascular disease risk communication in NHS health checks through video-stimulated recall interviews with patients - a qualitative study.
    Cowap L; Riley V; Grogan S; Ellis NJ; Crone D; Cottrell E; Chambers R; Clark-Carter D; Gidlow CJ
    BMC Prim Care; 2024 Apr; 25(1):126. PubMed ID: 38654245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein levels in patients at cardiovascular risk: EURIKA study.
    Halcox JP; Roy C; Tubach F; Banegas JR; Dallongeville J; De Backer G; Guallar E; Sazova O; Medina J; Perk J; Steg PG; Rodríguez-Artalejo F; Borghi C
    BMC Cardiovasc Disord; 2014 Feb; 14():25. PubMed ID: 24564178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses.
    Garg N; Muduli SK; Kapoor A; Tewari S; Kumar S; Khanna R; Goel PK
    Indian Heart J; 2017; 69(4):458-463. PubMed ID: 28822511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting.
    Samani NJ; Beeston E; Greengrass C; Riveros-McKay F; Debiec R; Lawday D; Wang Q; Budgeon CA; Braund PS; Bramley R; Kharodia S; Newton M; Marshall A; Krzeminski A; Zafar A; Chahal A; Heer A; Khunti K; Joshi N; Lakhani M; Farooqi A; Plagnol V; Donnelly P; Weale ME; Nelson CP
    Eur Heart J; 2024 Jun; ():. PubMed ID: 38848106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.
    Hippisley-Cox J; Coupland C; Vinogradova Y; Robson J; Minhas R; Sheikh A; Brindle P
    BMJ; 2008 Jun; 336(7659):1475-82. PubMed ID: 18573856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.
    Halcox JP; Tubach F; Lopez-Garcia E; De Backer G; Borghi C; Dallongeville J; Guallar E; Medina J; Perk J; Sazova O; Sweet S; Roy C; Banegas JR; Rodriguez-Artalejo F
    PLoS One; 2015; 10(2):e0115270. PubMed ID: 25692692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus.
    Edwards N; Langford-Smith AWW; Parker BJ; Bruce IN; Reynolds JA; Alexander MY; McCarthy EM; Wilkinson FL
    Lupus Sci Med; 2018; 5(1):e000272. PubMed ID: 30167314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential impact of new national guidance on primary prevention of cardiovascular disease in people living with HIV.
    Ahmed N; Bradley S; Pearson P; Edwards S; Waters L
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19713. PubMed ID: 25397460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease risk communication in NHS Health Checks: a qualitative video-stimulated recall interview study with practitioners.
    Gidlow CJ; Ellis NJ; Riley V; Cowap L; Crone D; Cottrell E; Grogan S; Chambers R; Calvert S; Clark-Carter D
    BJGP Open; 2021 Oct; 5(5):. PubMed ID: 34172476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA).
    Rodríguez-Artalejo F; Guallar E; Borghi C; Dallongeville J; De Backer G; Halcox JP; Hernández-Vecino R; Jiménez FJ; Massó-González EL; Perk J; Steg PG; Banegas JR;
    BMC Public Health; 2010 Jun; 10():382. PubMed ID: 20591142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?
    van Staa TP; Gulliford M; Ng ES; Goldacre B; Smeeth L
    PLoS One; 2014; 9(10):e106455. PubMed ID: 25271417
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.